Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal

Executive Summary

The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug
Advertisement

Related Content

AERS Database Cannot Determine Adverse Event Incidence, FDA Says In Rejecting Statin Label Warning
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go
Public Citizen seeks Crestor investigation
Crestor European Label Changes Prompt FDA Public Health Advisory
AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen
AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen
AstraZeneca Agrees To Limit Distribution, Promotion Of Crestor 40 Mg
AstraZeneca Crestor Plan: Drop 80 Mg, Submit Lower-Dose Data In Q1
Statin Consumer Medication Guides Requested By HRG In Wake Of Baycol
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Advertisement
UsernamePublicRestriction

Register

PS044006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel